MarketPulse

organ transplant

2 articles
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

TransMedics Soars 104% as Organ Transplant Monopoly Justifies Premium Valuation

TransMedics surges 104% on organ transplant dominance and 32% growth, but 56x forward earnings premium and 25% short interest raise sustainability questions for 2026.
TMDXvaluationmarket share
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

TransMedics Expands Organ Preservation Technology Amid Fleet Investment

TransMedics expands organ preservation technology platform and invests in dedicated aircraft transportation to improve transplant logistics and organ utilization rates.
TMDXregulatory approvalhealthcare innovation